Sentences with phrase «completed share repurchases»

Firms that completed share repurchases between 2002 and 2006, however, have not generated any better returns since that time than those who did not.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Not exact matches

The company also approved a new $ 40 billion share buyback program, reaffirming it's on track to complete its current $ 40 billion stock repurchase program by December 31.

Maestri said that since Apple has now completed $ 275 billion of its $ 300 billion capital return program, including $ 200 billion in share repurchases, Apple will complete its original plan three quarters early, in June.

Ingram will suspend its quarterly dividend payment and its share repurchase program until the deal is complete.

the Company's significant strategic accomplishments in 2011, including returning $ 5.0 billion to stockholders in the form of a 140 % common stock dividend increase and repurchasing 86 million common shares, successfully completing the Wachovia merger integration, and implementing the Company's expense management and efficiency initiative; and

A shareholder proposal by Carl Icahn of a non-binding advisory resolution that the Company commit to completing not less than $ 50 billion of share repurchases during its 2014 fiscal year (and increase the authorization under its capital return program accordingly)(Proposal No. 10); and

«RESOLVED, that the shareholders hereby approve, on an advisory basis, High River's proposal that Apple commit to completing not less than $ 50 billion of share repurchases during Apple's fiscal year ending September 27, 2014 (and increase the amount authorized for share repurchases under its Capital Return Program accordingly).»

A proposal by Carl Icahn of a non-binding advisory resolution that the Company commit to completing not less than $ 50 billion of share repurchases during its 2014 fiscal year (and increase the authorization under its capital return program accordingly)

Add in that Amazon is diluting shareholders by one percent in the last twelve months, versus Macy's which is returning capital through dividends and share repurchases at a rate of twelve percent, and you get a complete picture of why Macy's looks attractive to a value investor.

The Company will complete the execution of the previous $ 210 billion share repurchase authorization during the third fiscal quarter.

The company completed its prior $ 100 million share repurchase authorization during the quarter and purchased 650,000 shares under the new program for $ 14 million and another $ 6.9 million since quarter end.

Coca Cola has already completed about $ 1.5 billion worth of net share repurchases this year, and has another $ 1 billion to $ 1.5 billion expected for the next two quarters.

The Board made this decision after completing an exhaustive evaluation of various strategic alternatives available to the Company for enhancing stockholder value, including but not limited to, continued execution of the Company's business plan, the payment of a cash dividend to the Company's stockholders, a repurchase by the Company of shares of its capital stock, the sale or spin off of Company assets, partnering or other collaboration agreements, a merger, sale or liquidation of, or acquisition by, the Company or other strategic transaction.

The operating loss continued at 2nd quarter levels (staff downsizing has not yet been implemented and won't be complete until 6/12) and the share repurchase program continued with the purchase of 2.5 million shares at an average cost of $ 10.